Tempest Therapeutics, Inc.
TPST-2003
relapsed/refractory multiple myeloma
Resolved
7days ago
Phase 3 readout · Jun 30, 2026
What's at stake
Phase 3 trial results for TPST-2003 in relapsed/refractory multiple myeloma are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Submit a U.S. IND application and, subject to clearance, initiate a Phase 2b U.S. registrational study of TPST-2003 in patients with rrMM in 2026”